Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JDB0131 vs delamanid in rifampicin-resistant tuberculosis
NCT07170800Phase 2Recruiting
- Sponsor
- WestVac Biopharma
- Start
- Sep 2025
- Primary completion
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of JDB0131 in Tuberculosis (TB), sponsored by WestVac Biopharma. Started Sep 2025; status: recruiting.
02
Drugs
JDB0131
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT07170800.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07170800.